Polyheterocyclic compounds as METTL3 inhibitors

Compounds developed to inhibit METTL3 activity address the need for therapeutic agents in treating a range of diseases by modulating METTL3 activity, offering treatment options for cancer, autoimmune disorders, neurological diseases, and infectious diseases, including enhancing immune responses.

JP7765088B2Active Publication Date: 2025-11-06STORM THERAPEUTICS LIMITED
View PDF 9 Cites 1 Cited by

Patent Information

Application Number
JP2022532865
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-10-06
Filing Date
2020-12-01
Publication Date
2025-11-06
Estimated Expiration
2040-12-01

AI Technical Summary

Technical Problem

Current treatments lack effective inhibitors for METTL3 activity, which is implicated in various diseases such as cancer, autoimmune disorders, neurological diseases, and infectious diseases, and there is a need for therapeutic agents that can modulate METTL3 activity to treat these conditions.

Method used

Development of compounds that inhibit METTL3 activity, which can be used in pharmaceutical compositions to treat proliferative disorders, enhance immune responses, and treat diseases associated with METTL3 activity.

Benefits of technology

The compounds effectively inhibit METTL3 activity, providing therapeutic benefits in treating cancer, autoimmune diseases, neurological diseases, and infectious diseases, including enhancing anti-tumor and antiviral immune responses.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007765088000001
    Figure 0007765088000001
  • Figure 0007765088000002
    Figure 0007765088000002
  • Figure 0007765088000003
    Figure 0007765088000003
Patent Text Reader

Abstract

The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine methyltransferase 70 kDa subunit) enzyme activity: JPEG2023506147000602.jpg1826, where X, Y, and Z are as defined herein. The invention also relates to methods for making these compounds, pharmaceutical compositions containing them, and their use in the treatment of proliferative disorders such as cancer and autoimmune diseases, and other diseases or conditions in which METTL3 activity is implicated.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Indole as a modulator of nicotinic acetylcholine receptor subtype alpha-71

    JP2011516598A

  • Novel 1,2,4-Oxadiazole Compounds and Methods of Use Thereof

    JP2011522818A

  • 1H-benzimidazole-5-carboxamide as an anti-inflammatory agent

    JP2012503627A

  • METTL3 inhibitor compounds

    JP2022528562A

  • Pyrrolo-pyridine derivatives for the treatment of cancer diseases

    WO2007048070A2

Cited By

  • Polyheterocyclic compounds as mettl3 inhibitors

    JP2026027269A